From the publishers of JADPRO

Metastatic Triple-Negative Breast Cancer Resource Center

Advertisement

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

As reported in The New England Journal of Medicine by Aditya Bardia, MD, and colleagues, the phase III ASCENT trial has shown prolonged progression-free and overall survival with the Trop-2–directed antibody-drug conjugate sacituzumab govitecan-hziy vs single-agent chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer without brain metastases (primary trial population).

New England Journal of Medicine
Advertisement
News & Literature Highlights
Advertisement
Advertisement